



**HAL**  
open science

## Evaluating the role of Toll-like Receptors in diseases of the Central Nervous system

Michael Carty, Andrew G. Bowie

► **To cite this version:**

Michael Carty, Andrew G. Bowie. Evaluating the role of Toll-like Receptors in diseases of the Central Nervous system. *Biochemical Pharmacology*, 2011, 81 (7), pp.825. 10.1016/j.bcp.2011.01.003. hal-00678043

**HAL Id: hal-00678043**

**<https://hal.science/hal-00678043>**

Submitted on 12 Mar 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

Title: Evaluating the role of Toll-like Receptors in diseases of the Central Nervous system

Authors: Michael Carty, Andrew G. Bowie

PII: S0006-2952(11)00036-0  
DOI: doi:10.1016/j.bcp.2011.01.003  
Reference: BCP 10799

To appear in: *BCP*

Received date: 5-11-2010  
Revised date: 4-1-2011  
Accepted date: 6-1-2011

Please cite this article as: Carty M, Bowie AG, Evaluating the role of Toll-like Receptors in diseases of the Central Nervous system, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2011.01.003

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1  
2  
3  
4 **Evaluating the role of Toll-like Receptors in diseases of the Central**  
5  
6  
7 **Nervous system**  
8  
9

10  
11 Michael Carty\* and Andrew G. Bowie

12  
13  
14 School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland.  
15  
16  
17

18  
19  
20 **\*Corresponding Author**  
21

22 Michael Carty

23  
24  
25 School of Biochemistry and Immunology

26  
27 Trinity College Dublin

28  
29  
30 Dublin 2

31  
32  
33 Ireland

34  
35  
36 Ph: +353-1-8963047

37  
38  
39 FAX: +353-1-6772400

40  
41  
42 Email: [carty@tcd.ie](mailto:carty@tcd.ie)  
43  
44  
45

46  
47 **Short title**  
48

49 Toll-like receptors and CNS diseases  
50  
51  
52  
53

54  
55 **Keywords**  
56

57 Innate immunity, Toll-like receptor, infectious, non-infectious, diseases, central nervous system  
58  
59  
60  
61

## Abstract

A key part of the innate immune system is a network of pattern recognition receptors (PRRs) and their associated intracellular signalling pathways. Toll-like receptors (TLRs) are one such group of PRRs that detect pathogen associated molecular patterns (PAMPs). Activation of the TLRs with their respective agonists results in the activation of intracellular signalling pathways leading to the expression of proinflammatory mediators and anti-microbial effector molecules. Activation of the innate immune system through TLRs also triggers the adaptive immune response, resulting in a comprehensive immune program to eradicate invading pathogens. It is now known that immune surveillance and inflammatory responses occur in the central nervous system (CNS). Furthermore it is becoming increasingly clear that TLRs have a role in such CNS responses and are also implicated in the pathogenesis of a number of conditions in the CNS, such as Alzheimer's, stroke and multiple sclerosis. This is likely due to the generation of endogenous TLR agonists in these conditions which amplifies a detrimental neurotoxic inflammatory response. However TLRs in some situations can be neuroprotective, if triggered in a favourable context. This review aims to examine the recent literature on TLRs in the CNS thus demonstrating their importance in a range of infectious and non-infectious diseases of the brain.

## 1. Introduction

The survival of an organism critically depends on its ability to defend itself from invading pathogens. In higher organisms this is provided by the existence of an innate and adaptive immune system. The innate immune system is composed of a series of germ line encoded pattern recognition receptors (PRRs) that can detect conserved pathogen associated molecular patterns (PAMPs) expressed on microorganisms. The adaptive immune systems responds to microbial infection by expressing antigen receptors through somatic recombination and is characterised by the existence of immunological memory. Activation of the innate immune system leads to the production of inflammatory mediators, antimicrobial effectors and orchestration of the adaptive immune response leading ultimately to pathogen elimination. Several important PRRs of the innate immune system include Toll-like receptors (TLRs), Rig like Receptors (RLRs), Nod-like Receptors (NLRs) [1] and the recently identified Aim2 like receptors (ALRs) [2]. Although these PRRs, which have similarities and differences in terms of protein domain structure and subcellular localisation, they act together to defend against invading pathogens (figure 1). For example TLRs consist of leucine rich repeats (LRRs) and a Toll-Interleukin 1 receptor (TIR) domain and are located on the cell surface and endosomes. RLRs contain a helicase and CARD domains and are located in the cytoplasm. The cytoplasmic NLRs consist of NACHT, PYRIN, LRRs and CARD domains. Finally ALRs contain a PYRIN domain and HIN domains and are also located in the cytoplasm (figure1).

The family of TLRs was initially discovered in *Drosophila*, where *Toll*, was shown to have a role in dorsal-ventral polarity. It was then discovered that *Toll* showed similarity to the human

1  
2  
3  
4 interleukin-1 receptor. Later it was shown that *Drosophila Toll* did have a role in immunity, in  
5  
6 particular against fungal infection and this led to the search for human Toll-like receptors, the  
7  
8 first of which was discovered in 1997 [3]. It is now known that there are 10 functional TLRs in  
9  
10 humans and 12 in mice. TLR1-9 are conserved in both human and mice, mouse TLR10 is non  
11  
12 functional, while TLR11, 12 and 13 are not present in the human genome [4].  
13  
14  
15  
16  
17

18  
19 TLRs detect a wide range of PAMPs that are found on bacteria, viruses, fungi and parasites  
20  
21 which include proteins, lipids, lipoproteins and nucleic acids. TLRs are expressed on a variety of  
22  
23 immune and non immune cells such as monocytes, dendritic cells (DCs), epithelial cells and  
24  
25 fibroblasts. TLRs are found either on the cell surface or in intracellular compartments in  
26  
27 endosomes. These receptors function as hetero or homodimers, for example TLR1/2 and TLR2/6  
28  
29 heterodimers are found on the cell surface and detect triacyl and diacyl lipoproteins respectively  
30  
31 (figure 2). TLR4 and TLR5 are also found on the cell surface and detect lipopolysaccharide and  
32  
33 flagellin respectively (figure 2). By contrast the endosomal TLRs detect nucleic acids. TLR3  
34  
35 detects double strand RNA (dsRNA) and its synthetic analog, polyinosine-deoxycytidylic acid  
36  
37 (polyI:C), TLR7 and 8 detects viral single stranded RNA while TLR9 detects unmethylated CpG  
38  
39 dinucleotides of microbial origin [4] (figure 3).  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **1.1 TLR signalling**

49  
50  
51  
52

53 TLRs are type 1 membrane spanning receptors that consist of extracellular LRRs, a  
54  
55 transmembrane domain and a cytoplasmic TIR domain, the presence of which defines  
56  
57 membership of the family. Downstream signalling is achieved by the presence of cytoplasmic  
58  
59 TIR containing adaptor proteins. Five of these proteins exist MyD88, Mal, TRIF, TRAM and  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 SARM. MyD88 is the prototypical member of the group and is required to transmit all TLR  
5  
6 signals with the exception of TLR3 which uses TRIF only. Both TLR2 and TLR4 require Mal as  
7  
8 a bridging adapter to MyD88. In contrast TLR4 signalling following LPS stimulation requires  
9  
10 Mal, MyD88 and TRAM as a bridging adapter to TRIF to mediate MyD88 independent  
11  
12 signalling [5]. All TIR adaptors have important positive roles in mediating intracellular signalling  
13  
14 following TLR stimulation except SARM, which has been reported to inhibit TRIF dependent  
15  
16 TLR signalling [6].  
17  
18  
19  
20  
21  
22

23  
24 Upon TLR stimulation the respective adaptors are recruited to the cytoplasmic tails of the  
25  
26 receptors. This leads to the recruitment of IL-1 receptor-associated kinases (IRAKs). IRAK4  
27  
28 recruitment to MyD88 leads to the phosphorylation of IRAK1 and an association with TRAF6.  
29  
30 TRAF6 is an ubiquitin E3 ligases and with its E2 counterparts Uev1A and Ubc13 triggers the  
31  
32 ubiquitination of both TRAF6 itself and other substrates. This non degradative K63 linked  
33  
34 ubiquitinated TRAF6 induces the recruitment of TAB2 and TAB3 via specific ubiquitin-binding  
35  
36 domains. The degradation of IRAK1 allows this TRAF6 complex to move into the cytosol. In  
37  
38 addition to IRAK1, IRAK2 has an important role in this process as it has been shown to be  
39  
40 required for TRAF6 ubiquitination and NF $\kappa$ B activation [7]. Through TAB2/3, TAK1 is recruited  
41  
42 to the TRAF6 complex and activated. This in turn allows TAK1 to stimulate the activity of the  
43  
44 kinases complex of IKK $\alpha$  and  $\beta$ , through the regulatory subunit NEMO. This results in the  
45  
46 phosphorylation and degradation of the NF $\kappa$ B inhibitor I $\kappa$ B $\alpha$ . This permits the translocation of  
47  
48 NF $\kappa$ B into the nucleus to activate the expression of pro-inflammatory cytokines. In addition  
49  
50 TAK1 can activate the p38 and JNK MAP kinase pathways through the phosphorylation of  
51  
52 MKK3/6 and MKK4 respectively. Alternatively TLR activation of the ERK MAP kinase  
53  
54 pathway is dependent upon Tpl2 acting through MKK1/2 [8]. A separate pathway to NF $\kappa$ B and  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 MAP kinase activation following TLR3 and TLR4 stimulation is mediated by TRIF. This adaptor  
5  
6 initiates a signalling cascade through RIP1 binding, and through its adaptor TRADD, triggers  
7  
8 K63 linked ubiquitination of RIP1, which is independent of TRAF6. This allows the recruitment  
9  
10 of TAB2 and subsequent activation of TAK1, thus allowing IKK and MAP kinase activation. In  
11  
12 addition RIP1 can also activate NF $\kappa$ B through FADD and caspase 8. Stimulation of TLRs leads  
13  
14 to the production of type 1 interferons (IFN $\alpha/\beta$ ). Production of these mediators following TLR3  
15  
16 and TLR4 stimulation relies on the MyD88 independent TRIF pathway. Following TLR3 and  
17  
18 TLR4 stimulation TRIF recruits TRAF3. This results in K63 linked polyubiquitination of TRAF3  
19  
20 and the recruitment of TANK, NAP1 and SINTBAD. This allows the movement of TBK1 and  
21  
22 IKK $\epsilon$  to the receptor complex. This complex activates TBK1 and IKK $\epsilon$  which are the kinases for  
23  
24 IRF3 and IRF7. Phosphorylation of these transcription factors lead to their dimerisation and  
25  
26 translocation into the nucleus resulting in the expression of IFN $\alpha/\beta$  (for a recent review see [9]).  
27  
28 It is important to note that all type 1 interferon production following TLR stimulation, including  
29  
30 that followed by TLR4 stimulation, is initiated at the endosome (Figure 2 and 3).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 **1.2 TLR expression in cells of the brain**

42  
43  
44  
45 TLRs expression has been found in many cell types of the brain in both mice and humans and a  
46  
47 number of substantial differences in TLR expression have emerged between these species. For  
48  
49 example human astrocytes only express TLR3 mRNA [10] whereas murine astrocytes express  
50  
51 TLR2, 4, 5 and 9 mRNA [11]. Murine primary cortical neurons express TLR2, 3 and 4 at the  
52  
53 mRNA and protein level [12]. TLR2 and TLR6 protein was also shown to be expressed in  
54  
55 primary brain neurons under control conditions, while protein levels for TLR4, 7 and 8 was  
56  
57 induced by parasitic infection [13]. In contrast human neurons only express TLR3 [14], while  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 both mouse and human microglia express mRNA for TLR1-9 [15] [16] (Table 1). The  
5  
6 expression of TLR3 is particularly interesting as it is highly expressed in both murine and human  
7  
8 astrocytes and highly expressed in the resting CNS [17] suggesting that it may have vital immune  
9  
10 or homeostatic roles in the brain.  
11  
12  
13  
14

## 15 16 **2 Inflammation in the brain** 17 18

19  
20 While it was once thought that the brain and CNS were immune privileged it is now known that  
21  
22 immune surveillance and inflammatory responses occur in the brain [18] [19]. Acute  
23  
24 inflammation in the brain is protective, since it removes pathogens, cellular debris and leads to  
25  
26 tissue repair. However prolonged inflammation in the brain causes progressive neurotoxicity  
27  
28 leading to irreversible neuronal loss observed in neurodegenerative disease [20]. This is due to  
29  
30 the exquisite sensitivity of neurons to inflammatory molecules such as reactive oxygen species  
31  
32 (ROS) and the limited ability of the brain to regenerate neurons [19]. While neurogenesis occurs  
33  
34 primarily in development, the growth of new neurons occurs throughout adult life. The  
35  
36 inflammatory mediators released during mild acute inflammation promote neurogenesis, while  
37  
38 the inflammatory mediators released during prolonged inflammation inhibits neurogenesis [21].  
39  
40 New neurons are generated from neural progenitor cells (NPCs) and this is affected by the  
41  
42 inflammatory process. Not alone do neurons need to be newly generated but these neurons must  
43  
44 differentiate, migrate, survive and integrate correctly into the CNS circuitry in order to be  
45  
46 functionally relevant and therefore constitute successful neurogenesis [21]. For example although  
47  
48 in Alzheimer's disease (AD) there is an increase in neurogenesis, these neurons do not mature  
49  
50 and survive [21]. Therefore the brain is sensitive to prolonged inflammation and thus this process  
51  
52 must be tightly regulated.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 TLRs are expressed and elicit functional signalling pathways in the CNS [18], and it has been  
8  
9 suggested that TLRs might be the initial trigger for inflammation in the CNS. The observation  
10  
11 that TLR expression is increased in the brains of patients with AD and the brain and spinal cords  
12  
13 of multiple sclerosis (MS) patients supports this notion and also suggests that TLRs may be  
14  
15 involved in the progression of these diseases [18]. It is noteworthy that controlled inflammation  
16  
17 plays a role in protecting neurons in the CNS [18], hence in some situations TLRs might confer a  
18  
19 neuroprotective immune response. In addition there is evidence to suggest that TLRs expressed in  
20  
21 the brain have functions distinct from immunity, for example, TLRs are functional in adult  
22  
23 neurogenesis [18] and TLR 8 expression on neurons triggers apoptosis suggesting a role in CNS  
24  
25 homeostasis [18]. With regard to infectious diseases, TLR9 activation may be involved in the  
26  
27 induction of meningitis and TLR3 expression is enhanced during infection with rabies or herpes  
28  
29 simplex virus [18]. These observations all indicate that TLRs are important in infectious and non  
30  
31 infectious diseases of the brain. This review aims to provide a brief summary of the role that  
32  
33 TLRs play in some of these illnesses.  
34  
35  
36  
37  
38  
39  
40  
41  
42

## 43 **2.1 Tissue damage releases endogenous TLR ligands**

44  
45  
46  
47  
48 It is becoming increasingly clear that TLRs are activated by endogenous ligands generated in  
49  
50 situations of sterile inflammation. Examples of these ligands include heat shock proteins (HSPs),  
51  
52 fibrinogen, fibronectin, soluble hyaluronan, oxidized LDL, mRNA, gangliosides, fatty acids and  
53  
54 high mobility group box 1 protein (HMGB1) [18] [19]. These danger associates molecular  
55  
56 patterns (DAMPs) are release from dying cells and stimulate TLRs on microglia to produce  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 neurotoxic inflammatory mediators [19]. This model is supported by the observation that HSP60,  
5  
6 released from dying cells of the CNS and stimulates TLR4 on microglia to trigger the production  
7  
8 of nitric oxide (NO) which is toxic to neurons [22]. Therefore by the release of these “alarmins”,  
9  
10 this intrinsic activation of TLRs serves to amplify the inflammatory response in the absence of  
11  
12 infection and contribute to inflammatory diseases of the brain.  
13  
14  
15  
16  
17  
18

## 19 **2.2 Role of Microglia in inflammation**

20  
21  
22  
23

24 Microglia are a vital part of immunity in the CNS as they can activate both innate and adaptive  
25  
26 immune responses. Microglia express many TLRs and are the resident macrophages of the CNS.  
27  
28 Under normal conditions in the CNS these cells are inactive and express low levels of MHC and  
29  
30 co-stimulatory molecules. These inactive microglia are important in immune surveillance as they  
31  
32 constantly monitor the CNS microenvironment through pinocytosis. Infection or injury in the  
33  
34 CNS results in the activation of microglia leading to their increased proliferation, motility,  
35  
36 phagocytosis and release of cytokines and ROS [23]. Activation of microglia also results in  
37  
38 increased expression of MHC and co-stimulatory molecules and stimulates CD4 and CD8 T cell  
39  
40 responses, and therefore serve as important APCs of the CNS [23]. Microglia are of  
41  
42 myelomonocytic origin and in addition to TLRs, these cells express CD11b and CD45 [23]. It has  
43  
44 been noted that microglia are activated in all diseases of the CNS and they are among the first  
45  
46 cells found at the site of tissue injury and infection, and function to recruit other immune cells  
47  
48 [19]. It has also been found that activation of TLRs on microglia can result in injury to neurons  
49  
50 and oligodendrocytes [19].  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3. TLRs in Alzheimer's disease

AD is the most common neurodegenerative disease which is characterised by progressive neuronal death and memory loss. Although the etiology of the disease is unknown, accumulation of  $\beta$  amyloid ( $A\beta$ ), leads to the development of extracellular senile plaques and intracellular neurofibrillary tangles.  $A\beta$  is a 42 amino acid ( $A\beta_{42}$ ) fragment derived from the amyloid precursor protein [24] [25] and it is the inflammatory response to this pathological agent that is central to the disease [26]. Microglia are found in an activated state around senile plaques in the brains of AD patients and are considered to be important in the pathogenesis of the disease. Activation of microglia results in the production of NO, oxygen free radicals, proteases, adhesion molecules and proinflammatory cytokines such as  $TNF\alpha$ ,  $IL-1\beta$ ,  $LT-\alpha$ , and  $IL-6$  [27-31]. It is thought that the overproduction of these inflammatory mediators is important in the degenerative process in patients with AD [32].

#### 3.1 Role for TLRs in Alzheimer's disease

There is a growing body of evidence that suggests that TLRs are important in AD, in particular those TLRs that are expressed in microglia. For example animal models of AD and patients with AD exhibit increased expression of CD14, (a co-receptor for TLR4), TLR4 and TLR2 [33-36], which are thought to occur independently in response to the presence of  $A\beta$ . Interestingly a polymorphism in TLR4 Asp299Gly resulted in a 2.7 fold reduction in risk for late onset AD [37]. Senile plaque associated microglia show increased mRNA levels of TLR 2, 4, 5, 7 and 9 [38] and

1  
2  
3  
4 a physical interaction between CD14 and fibrillar A $\beta$  (FA $\beta$ ) was demonstrated by Reed Geaghan  
5  
6 et al [39]. The signal transduction cascades triggered by FA $\beta$  is identical to those triggered by  
7  
8 TLR agonists [39] and A $\beta$  induction of NF $\kappa$ B dependent genes requires TLR2, TLR4 and CD-14  
9  
10 [39], thus indicating that TLRs are important in sensing and responding to the presence of A $\beta$ .  
11  
12  
13  
14  
15  
16

17 Studies in primary mouse microglia and BV-2 microglia cells showed that TLR2 mediates  
18  
19 activation of microglia in response to FA $\beta$ , leading to the expression of proinflammatory  
20  
21 cytokines, inducible NO synthase and integrin markers. This response was dependent upon  
22  
23 MyD88 and microglia from mice lacking TLR2 were not activated by FA $\beta$  [32]. Furthermore in a  
24  
25 functional screen using antisense knockdown, while knockdown of TLR2 reduced TNF release in  
26  
27 microglia stimulated with FA $\beta$ , knockdown of TLR 4, 6, 7 and 9 had no such effect [32].  
28  
29  
30  
31  
32  
33  
34  
35

36 A role for CD14 in AD was demonstrated as CD14 associates with A $\beta$  and is involved in the  
37  
38 phagocytosis of A $\beta$ . Immunohistochemical staining of brains of AD patients showed strong  
39  
40 expression of CD14 in senile plaques and parenchymal microglia which was not observed in age  
41  
42 matched controls [34].  
43  
44  
45  
46  
47  
48  
49

50 Further evidence suggesting a role for TLRs in microglial responses to A $\beta$  was provided in a  
51  
52 study where microglia derived from TLR2, 4 and CD14 KO mice were defective in Src-Vav-Rac  
53  
54 and p38 MAPK signalling and showed reduced ROS production and phagocytosis in response to  
55  
56 FA $\beta$  [39]. This suggests that TLR2, TLR4 and CD-14 are part of the receptor complex that  
57  
58 responds to FA $\beta$ . This cellular complex also consists of cell surface receptors such as CD36,  $\alpha_6\beta_1$   
59  
60  
61

1  
2  
3  
4 integrin, CD47 and scavenger receptor A, which, along with TLRs 2, 4 and CD14 can bind to  
5  
6 FA $\beta$  to trigger multiple intracellular signaling cascades [39-41].  
7  
8  
9

10  
11  
12  
13 The G protein-coupled formyl peptide receptor-like 1 (FPRL1) and its mouse homologue mFPR2  
14  
15 is a receptor and mediates the internalisation of A $\beta$  peptide, suggesting that this receptor may be  
16  
17 important in the disease progression of AD. In addition FPRL1 mediates the chemoattractive  
18  
19 activity of microglia in response to A $\beta$  peptide which may lead to the recruitment of microglia to  
20  
21 AD lesions. Interestingly stimulation of both TLR2 and TLR4 lead to the upregulation of mFPR2  
22  
23 and enhances the uptake of A $\beta$  peptide and increases the chemotactic functions of microglia [42,  
24  
25 43]. The authors of these studies propose that activation of TLR2 and TLR4 on microglia may  
26  
27 promote microglial responses in the CNS especially in pathological situations such as AD where  
28  
29 the A $\beta$  agonists for mFPR2 are elevated, and thereby amplify the inflammatory response in AD  
30  
31 [43]. This intrinsic TLR activation may be mediated by a range of host derived molecules which  
32  
33 may activate TLR2 and TLR4, such as HSP60, HSP70, GP96 and HMGB1, which are all  
34  
35 increased in inflammatory conditions [43].  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Though most studies of TLRs in AD have focused on microglia, TLRs may be important in the  
48  
49 disease progression of AD that are expressed on cells of the CNS other than microglia. For  
50  
51 example TLR4 was shown to mediate neuronal apoptosis in response to A $\beta$ <sub>42</sub> [44], indicating a  
52  
53 complex relationship between the various cells expressing TLRs in the presence of A $\beta$ . In AD it  
54  
55 is proposed that CD14 is a double edged sword. While the role of CD14 in the phagocytosis of  
56  
57 A $\beta$  is thought to be beneficial, CD14 mediated cellular activation and release of neurotoxic  
58  
59  
60  
61

1  
2  
3  
4 products is thought to be detrimental [34]. The authors propose that in early disease that low  
5  
6 concentrations of A $\beta$  might trigger CD14 dependent phagocytosis of A $\beta$  peptide, while in more  
7  
8 advanced AD, higher concentrations of A $\beta$  may lead to CD14 dependent cellular activation and  
9  
10 release of neurotoxic mediators [34].  
11  
12  
13  
14  
15

### 16 **3.2 Unanswered Questions in Alzheimer's disease**

17  
18  
19  
20

21 It is currently unknown why microglia in AD fail to phagocytose and clear A $\beta$  deposits in the  
22  
23 brain since microglia *in vitro* are proficient in this function [41]. It is thought that phagocytosis of  
24  
25 A $\beta$  peptide by microglia is a mechanism of host defence, however long term exposure of  
26  
27 microglia to A $\beta$  peptide may result in fibrillary deposition [43]. It has been proposed that  
28  
29 clearance or deposition of A $\beta$  peptide may be determined by factors such as A $\beta$  peptide burden  
30  
31 and the duration of cell exposure [43]. Interestingly it has been reported that proinflammatory  
32  
33 cytokines reduces the function of the phagocytic machinery of microglia, which can be relieved  
34  
35 by anti-inflammatory cytokines, suggesting a possible strategy for the treatment of AD [45].  
36  
37 However it remains unknown if TLR induction of phagocytosis is impaired in AD [41],  
38  
39 thus raising the important question of whether inhibitors or modulators of TLRs or their signaling  
40  
41 pathway are produced in the brains of AD patients. A number of studies have reported that TLR  
42  
43 activation is associated with increased clearance of A $\beta$ , which combined with some indications  
44  
45 that TLRs are somehow dysfunctional in AD, raises the prospect that the use of TLR agonists  
46  
47 may be beneficial in AD [46]. Thus in the future it may be possible to develop therapeutics that  
48  
49 enhance TLR dependent microglial phagocytosis of A $\beta$  and yet limit the release of neurotoxic  
50  
51 proinflammatory cytokines. In this regard an interesting recent study has shown that the TLR9  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 agonist CpG increased phagocytosis of A $\beta$  without the accompanying release of the neurotoxic  
5  
6  
7 NO or glutamate [47].  
8  
9

#### 10 11 **4. TLRs in Multiple sclerosis** 12 13 14

15  
16  
17 Multiple sclerosis (MS) is an inflammatory demyelinating disease and while the exact cause is  
18  
19 unknown, an environmental or infectious based etiology has been proposed [48]. The  
20  
21 pathogenesis of the disease is based on cell mediated immunity. The disease may occur in a  
22  
23 relapsing-remitting form or in a progressive form where disease severity worsens over time [48].  
24  
25 The disease pathogenesis occurs in two main stages, the initial priming/activation phase in which  
26  
27 self reactive lymphocytes are activated and a later effector phase where these cells invade the  
28  
29 CNS and cause tissue destruction. DCs play a vital part of the initial T cell priming phase and  
30  
31 maintenance of the disease process. Activation of these DCs occurs due the presence of  
32  
33 endogenous danger signals which leads to the breakdown of tolerance and the development of an  
34  
35 autoimmune response [49].  
36  
37  
38  
39  
40  
41  
42  
43

44  
45 In order to study MS, mouse models are employed where experimental autoimmune encephalitis  
46  
47 (EAE) is triggered by the injection of myelin proteins together with complete freunds adjuvant  
48  
49 (CFA) containing *Mycobacterium tuberculosis*, which lead to the development of myelin specific  
50  
51 CD4+T cells [50]. In EAE Th17 cells are particularly important for the induction of the disease  
52  
53 [48] and these cells enter the CNS after Th1 cells[51]. However the importance of Th17 cells in  
54  
55 mouse models of autoimmune neuroinflammation is controversial [52].  
56  
57  
58  
59  
60  
61



1  
2  
3  
4 A number of studies have implicated TLR ligands in the development of EAE [53]. In support of  
5  
6 this, MyD88 knockout mice are completely resistant this disease, since they fail to develop Th1  
7  
8 and Th17, which are essential in the pathogenesis of EAE [54]. However while a role for TLR  
9  
10 signalling in the development of myelin specific Th17 cells has been established the stimulatory  
11  
12 TLRs for these Th17 cells have not yet been identified [54].  
13  
14

15  
16  
17  
18 While TLR signalling is required in EAE, the role of individual TLRs in the condition is more  
19  
20 complex. For example TLR4 knockout mice have greater disease severity which is associated  
21  
22 with increased Th17 function [54], while determining the contribution of TLR9 has produced  
23  
24 conflicting results [49, 54]. In contrast TLR3 stimulation is protective in EAE due to the  
25  
26 induction of IFN $\beta$  [55] which has led to the suggestion that TLRs inducing interferon is  
27  
28 protective, whereas TLR stimulation that leads to proinflammatory cytokine expression adds to  
29  
30 disease severity [56]. In addition to this, the immune cells which express TLRs have an important  
31  
32 bearing on the disease. In mice whose B cells are lacking MyD88 or TLR2 and TLR4, chronic  
33  
34 EAE develops, whereas those animals with TLR9 deficient B cells, recovered at a similar rate to  
35  
36 wild type (WT) mice [48, 57] (Table 2). This might be due to TLR dependent induction of IL-10  
37  
38 from B cells which prevents the release of IL-6 from DCs [57]. These data support a model  
39  
40 where TLR signalling in B cells may limit T cell mediated autoimmunity in EAE [48].  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 TLR signalling has been found to be necessary for the development of EAE triggered by the  
51  
52 injection of myelin proteins, however TLR agonists are present in the adjuvant preparations,  
53  
54 therefore it is difficult to extrapolate how data from these studies relate to the role of endogenous  
55  
56 TLR ligands, TLR receptors and TLR signalling in human multiple sclerosis. Since it is known  
57  
58  
59  
60  
61

1  
2  
3  
4 that TLR3 and TLR4 are upregulated in human MS [58], further work is required to establish the  
5  
6 significance of the TLR network in the human disease.  
7  
8  
9

## 10 11 **5. TLRs in Stroke**

12  
13  
14  
15  
16  
17 Stroke results from a loss in blood supply to a specific region of the brain that leads to ischaemic  
18  
19 injury (Bejot et al 2009). This causes metabolic stress and death in neurons resulting from lack of  
20  
21 ATP. This neuronal death is initially caused by necrosis and following ischaemia and  
22  
23 reperfusion, cell death occurs by apoptosis [59]. Stroke is a condition of complex pathology  
24  
25 and the outcome to stroke depends on multiple cell types and inflammatory mediators and these  
26  
27 factors can be detrimental or beneficial depending on the duration magnitude and timing of  
28  
29 response [59].  
30  
31  
32  
33

34  
35  
36 Ischaemia induced cells death triggers the activation of microglia, production of proinflammatory  
37  
38 cytokines such as  $\text{TNF}\alpha$ ,  $\text{IL-1}\beta$  and chemokines CCL2 and CCL3. This leads to the infiltration of  
39  
40 inflammatory cells such as leukocytes, macrophages and neutrophils from the periphery. These  
41  
42 cells release neurotoxic or neuroprotective mediators that affect the outcome to stroke. For  
43  
44 example infiltrating macrophages in stroke release  $\text{TNF}$  and  $\text{IL-1}\beta$ , and while it was shown that  
45  
46  $\text{IL-1}\beta$  is neurotoxic and inhibitors of  $\text{IL-1}\beta$  are beneficial, determining whether  $\text{TNF}\alpha$  has a  
47  
48 positive or negative effects is challenging and has produced conflicting results [59].  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61

1  
2  
3  
4 There is evidence to suggest that the recruitment of inflammatory cells to the injured site is  
5  
6 detrimental in the outcome to stroke [60]. Furthermore it was also shown that inhibition of IL-8,  
7  
8 NF $\kappa$ B, and decreased leukocyte infiltration all improve stroke outcome [59].  
9

10  
11  
12  
13  
14 As stated previously not only can TLRs sense infection but they can also sense tissue damage.  
15  
16 Microglia activation in stroke may be dependent on TLRs to trigger the release of a range of  
17  
18 inflammatory mediators to attract other immune cells to the site of injury [59]. Myeloid DCs are  
19  
20 recruited to the infarct site and mediate the recruitment of T cells by the release of IFN-  
21  
22  $\gamma$ . The presence of T cells at the infarct site is both beneficial and detrimental. Th1 cells  
23  
24 release the proinflammatory cytokines IL-2, TNF $\alpha$  and IFN- $\gamma$ , while Th2 cells produce  
25  
26 the anti-inflammatory cytokines IL-10 and IL-13. In addition Tregs produce the neuroprotective  
27  
28 IL-10, which is dependent upon TLR signalling [59].  
29  
30  
31  
32  
33  
34  
35

### 36 **5.1 Detrimental role for TLRs**

37  
38 During ischaemic injury the blood brain barrier (BBB) is disrupted due to the release of proteases  
39  
40 such as matrix metalloproteinases (MMPs). This results in the release of endogenous TLR  
41  
42 ligands into the periphery which may activate immune cells of the periphery bearing TLRs.  
43  
44 Therefore TLRs signalling activated after stroke occurs both in the periphery and the CNS and  
45  
46 has been suggested to be a bridge between both locations [59].  
47  
48  
49  
50  
51  
52

53 A variety of studies using mouse models for stroke suggest that the release of endogenous ligands  
54  
55 activate TLRs to contribute to the tissue injury caused in this condition. Many of these studies  
56  
57 have implicated important roles for TLR2 and TLR4 in this pathological process.  
58  
59  
60  
61

1  
2  
3  
4  
5  
6  
7 Following cerebral ischaemia TLR4 is activated by HMGB1 in neurons and astrocytes to trigger  
8  
9 the release of MMP9 [61]. In addition the authors also show infarct size was decreased in mice  
10  
11 with a missense mutation in TLR4 [61]. Consistent with this, mice lacking TLR4 but not those  
12  
13 lacking TLR3 or TLR9 were shown to have reduced infarct area following ischaemic challenge  
14  
15 [62, 63] (Table 2). In addition there was a reduction in the number of microglial cells at the  
16  
17 infarct site in mice lacking TLR4.  
18  
19  
20  
21  
22

23  
24 The expression of TLR2 is upregulated in cerebral ischaemia and similar to TLR4, mice lacking  
25  
26 TLR2 had smaller infarct size compared to WT mice [64]. The scavenger receptor CD36 is a co-  
27  
28 receptor for TLR1/2 and TLR2/6 heterodimers and cerebral injection of ligands for TLR1/2, but  
29  
30 not ligands for TLR2/6 or TLR4, produced an inflammatory response that was dependent on  
31  
32 CD36. This indicates that CD36 is necessary for TLR1/2 signalling in the brain [65] (Table 2).  
33  
34  
35  
36  
37

38  
39 Further support for a detrimental role of TLRs after stroke was provided in a study using animal  
40  
41 models of glucose and energy deprivation. The authors of this study showed that inhibition of  
42  
43 TLR2 and TLR4 on neurons prevented JNK activation and neuronal death after energy  
44  
45 deprivation [12].  
46  
47  
48  
49

50  
51 In the ischaemic brain the activation of NF $\kappa$ B but not IRF3 is increased, and this increase in  
52  
53 NF $\kappa$ B activation was shown to be independent of TRIF [63]. In addition neurological defects  
54  
55 and infarct size was not altered in mice lacking TRIF compared with controls when subjected to  
56  
57 ischaemic challenge. Furthermore an in vitro model of stroke where oxygen and glucose  
58  
59 deprivation is used, it was found that activation of the TRIF pathway by poly(I:C) reduced this  
60  
61

1  
2  
3  
4 mode of neuronal death [66]. Thus it appears that MyD88 dependent signalling after stroke is  
5  
6 detrimental while TRIF mediated signalling might be beneficial and therefore having important  
7  
8 implications for neuroprotection.  
9

## 10 11 12 13 14 **5.2 TLRs in neuroprotection**

15  
16  
17  
18  
19 It has been established that TLR activation after ischaemia by endogenous ligands contributes to  
20  
21 tissue damage in stroke. However TLR activation before ischaemia was shown to be protective  
22  
23 [66]. Systemic administration of LPS by intraperitoneal injection prior to ischaemic challenge  
24  
25 induced a neuroprotective response. The protective effect of LPS preconditioning is dependent on  
26  
27 TRIF and IRF3 and this neuroprotection is likely due to the production of type I interferons, as  
28  
29 direct intracerebroventricular administration of IFN $\beta$  at the onset of stroke is neuroprotective  
30  
31 [66]. In addition it was shown that Pam3CSK4 administration 24 hrs before cerebral ischaemia  
32  
33 reduced infarct size [63] and pretreatment of TLR9 agonists CpG before stroke also conferred  
34  
35 neuroprotection, at least partly due to the release of TNF alpha [67]. TLRs are also involved in  
36  
37 ischaemic preconditioning where ischaemia induced of a short duration provides resistance to  
38  
39 subsequent challenge thus conferring ischaemic tolerance [68]. This protective effect was shown  
40  
41 to be dependent upon TLR4 to upregulate TNF $\alpha$ , inducible NO synthase, cyclooxygenase 2 and  
42  
43 NF $\kappa$ B [68].  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

## 54 **6. TLRs and Glioma**

55  
56  
57  
58  
59  
60  
61

1  
2  
3  
4 Malignant glioma is the most common and most aggressive form of primary brain tumour in  
5  
6 adults which have a poor prognosis [69]. In these tumours there are high levels of infiltrating  
7  
8 microglia, yet in the immunosuppressive tumour microenvironment, these microglia are unable to  
9  
10 induce an effective anti-tumour T cell response [23]. The immunosuppressive properties of  
11  
12 glioma include, high levels of infiltrating Tregs and secretion of immunosuppressive TGF $\beta$  and  
13  
14 IL-10 [70, 71]. Other function of microglia that are inhibited by glioma include, phagocytosis,  
15  
16 antigen presentation and secretion of proinflammatory cytokines [23]. An effective  
17  
18 immunotherapy has been proposed to be one in which alleviates the immunosuppressive micro-  
19  
20 environment of glioma and yet triggers an effective anti-tumour immune response [71].  
21  
22  
23  
24  
25  
26  
27

28 A number of studies in mouse models of glioma have showed that direct intracranial injection of  
29  
30 CpG elicits potent anti-tumour effects [72]. These TLR9 agonists are powerful immune  
31  
32 stimulators that induce cytokine secretion which results in the activation of NK and T cell  
33  
34 responses [72]. In one such study a single intratumoral injection of CpG inhibited glioma growth  
35  
36 and cured 80% of mice with glioma [71]. The use of TLR9 KO mice showed that the effectiveness  
37  
38 of CpG was due to the expression of TLR9 on non tumour cells. In addition treatment with CpG  
39  
40 increased tumour infiltrating CD4<sup>+</sup> and CD8<sup>+</sup> effector T cells and increased the ratio of CD4<sup>+</sup>  
41  
42 effector T cells to regulatory T cells [71]. Interestingly, surviving mice treated with CpG and re-  
43  
44 challenged with glioma rejected the tumour which shows that CpG conferred a protective  
45  
46 immune memory [71]. In a similar study, multiple low doses intratumoral injection of CpG  
47  
48 eliminated gliomas in 70% of mice by inducing the effector functions of NK cells [73].  
49  
50  
51  
52  
53  
54  
55 Importantly the anti-tumour effect of CpG was shown to be dependent upon microglia [23].  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 The anti-glioma effect of TLR stimulation might not be limited to TLR9, as intratumoral  
5  
6 injection of Pam3Cys-SK4 or R848 to stimulate TLR1/2 and TLR7 respectively also showed  
7  
8 survival benefit. In contrast TLR3 stimulation with poly(I:C) or LPS stimulation of TLR4 failed  
9  
10 to show anti-tumour effects [71].  
11  
12  
13  
14

15  
16 In addition to microglia, DC function may also be augmented to surmount the  
17  
18 immunosuppressive environment of glioma and enhance the anti-tumour immune response. DCs  
19  
20 of the brain are located at the choroid plexus, the meninges and the perivascular spaces. These  
21  
22 cells are not normally found in the brain parenchyma but can be found at brain lesions [74].  
23  
24 TGF- $\beta$ 2 is a potent immunosuppressive cytokine that is produced by gliomas to inhibit T cell  
25  
26 function. *In vitro* stimulation of human DCs by a maturation cocktail containing the TLR ligands  
27  
28 Poly(I:C) or R848 with TNF $\alpha$ , IL-1 $\beta$  and IFN induced MHC II expression and IL-12 secretion,  
29  
30 that was unaffected by TGF- $\beta$ 2 [74]. This suggests that TLR stimulation of DCs may trigger an  
31  
32 effective immune response in the immunosuppressive environment of glioma [74].  
33  
34  
35  
36  
37  
38  
39  
40

41 In addition to studies in mice a number of human studies have been undertaken to determine the  
42  
43 relationship between TLR expressing microglia and glioma. Microglia from surgically resected  
44  
45 glioma showed TLR expression patterns similar to that of microglia from healthy individuals.  
46  
47 However compared with microglia from healthy individuals, glioma associated microglia  
48  
49 exhibited reduced tumour cytotoxicity, thus indicating that glioma impairs the function of  
50  
51 microglia [70]. In other human studies TLR9 mRNA expression levels have been evaluated in  
52  
53 glioma where it was found that in 37 patients TLR9 mRNA was expressed at different levels,  
54  
55 suggesting that evaluating TLR9 levels may identify patients more likely to better respond to  
56  
57 CpG treatment [72].  
58  
59  
60  
61

1  
2  
3  
4  
5  
6  
7 Promising results from mouse models of glioma treated with CpG-ODN have lead to the use of  
8  
9 CpG in clinical trials. A phase 1 clinical trial was undertaken using intratumoral administration of  
10  
11 CpG-28 in recurrent glioblastoma, which showed some response without adverse side effects.  
12  
13 [75]. In a follow-up phase II study, again using CpG-28 in recurrent glioblastoma, some response  
14  
15 in progression-free survival at 6 months was observed [76] (Table 3).  
16  
17  
18  
19  
20

21 So far we have evaluated ways in which TLR expressing microglia might be manipulated  
22  
23 therapeutically to trigger an anti-tumour immune responses, however some evidence actually  
24  
25 points to microglia mediating immunosuppression in glioma and possibly contributing to tumour  
26  
27 proliferation and progression [23]. It is thought that microglia through the production of MMPs,  
28  
29 VEGF and EGF may contribute to tumour migration, angiogenesis and proliferation respectively  
30  
31 [23]. It is also possible that endogenous TLR ligands produced from dying tumour cells such as  
32  
33 heat shock proteins and HMGB act on TLRs expressed on microglia to contribute to tumour  
34  
35 proliferation. Indeed it is established that TLRs can be both beneficial and detrimental in cancers  
36  
37 generally having both anti-tumour and pro-tumour effects [77].  
38  
39  
40  
41  
42  
43  
44

## 45 **7. Role of TLRs in Chronic pain**

46  
47  
48  
49

50 It was once thought that pain was mediated solely by neurons, however it is now becoming clear  
51  
52 that glial in the spinal cord contributes to the initiation and maintenance of pathological pain  
53  
54 from a variety of sources [78, 79]. Spinal cord glia are activated by sensory signals from the  
55  
56 periphery, and similar to infection, release proinflammatory cytokines that contribute to pain [78,  
57  
58 80]. Neuropathic pain in a chronic sensory disorder triggered by damage to sensory peripheral or  
59  
60  
61



1  
2  
3  
4 central nerves and leads to spontaneous pain and enhanced pain responses to both noxious and  
5  
6 innocuous stimuli [81]. This type of pain is not protective and is itself regarded as a pathological  
7  
8 condition [82]. In contrast to inflammatory pain, treatments for neuropathic pain is lacking, and  
9  
10 therefore is a requirement to understand its molecular pathogenesis [83]. It is now thought that  
11  
12 the basis of neuropathic pain requires immune activation in the CNS, where the production of  
13  
14 chemokines and cytokines triggers the expression of pain mediators such as glutamate and NO  
15  
16 [80, 84-86]. Critically proinflammatory cytokines such as TNF, IL-1 and IL-6 have not been  
17  
18 associated with the generation of normal non pathological pain, yet these mediators are all  
19  
20 associated with conditions where pain is exacerbated [78]. Furthermore stimulation of perispinal  
21  
22 microglia by bacterial cell walls or viral envelope proteins induces hyperalgesia (increased  
23  
24 sensitivity to pain) [78].  
25  
26  
27  
28  
29  
30

31  
32  
33 Animal models of neuropathic pain involve the use of L5 spinal nerve ligation and monitoring  
34  
35 behavioural sensitivity, a hallmark of neuropathic pain [86]. The use of animal models of  
36  
37 neuropathic pain reveal activation of microglia and astrocytes in the spinal cord and the  
38  
39 production of IL-1 $\beta$  and TNF $\alpha$  which are important in the initiation and maintenance of  
40  
41 neuropathic pain [82].  
42  
43  
44  
45  
46  
47

48  
49 Accumulating evidence indicates that TLRs have an important contribution to the development of  
50  
51 neuropathic pain. It is now thought that the release of endogenous DAMPs following nerve  
52  
53 damage leads to the activation of astrocytes and microglia via TLRs to increase the expression of  
54  
55 proinflammatory cytokines and chemokines which induces the production of pain mediators [86].  
56  
57  
58  
59  
60  
61

1  
2  
3  
4 It has been demonstrated using mouse and rat models of neuropathic pain that lack of TLR4  
5  
6 function reduces nerve injury induced pain sensitivity [87]. Using knockout mice it was shown  
7  
8 that CD14 contributes to TLR4 dependent nerve injury mediated neuropathic pain but not in the  
9  
10 nociception of physiological pain [86]. It was also shown that this role of CD14 was mediated by  
11  
12 TLR4 dependent pathways. However the endogenous ligand that triggers the CD14-TLR4  
13  
14 signalling pathway following nerve injury was not identified, but may include one or more of  
15  
16 HSPs, HMGB1, and  $\beta$  defensins [86]. The same study also showed that spinal cord microglia  
17  
18 become reactive following nerve injury induced neuropathic pain.  
19  
20  
21  
22  
23  
24  
25

26 Intriguingly it has been demonstrated that opioids activate microglia via TLR4 and morphine  
27  
28 induces TLR4 signalling in HEK 293 cells [82]. Opioid activation of microglia via TLR4  
29  
30 produces undesirable effects such as a reduction of opioid analgesia and increases opioid  
31  
32 tolerance, dependence, reward and respiratory depression [88]. Since the desired beneficial  
33  
34 effects of opioids are mediated by opioid receptors on neurons, Watkins and co-workers propose  
35  
36 that the desired effects of opioids may be separated from the unwanted side effects of TLR4  
37  
38 activation on glia by the use of TLR4 inhibitors. Furthermore the point is also made that the use  
39  
40 of such a strategy may be a useful treatment of neuropathic pain [88].  
41  
42  
43  
44  
45  
46  
47  
48

49 Antisense knockdown of TLR3 reduced the activation of spinal microglia and inhibited the  
50  
51 increase of spinal proinflammatory cytokines IL-1 $\beta$ , IL-6 and TNF $\alpha$  following nerve injury.  
52  
53 Interestingly intrathecal administration of the TLR3 agonist poly(I:C) produced many of the  
54  
55 features characteristic of nerve injury [83]. In addition TLR3 knockout mice failed to develop  
56  
57 tactile allodynia (painful response to non painful stimuli) after nerve injury or poly(I:C) injection.  
58  
59  
60  
61

1  
2  
3  
4 These data indicate that TLR3 is critical for the development of neuropathic pain [83]. Since  
5  
6 TLR3 binds mRNA released from necrotic cells it has been suggested that this may be the  
7  
8 mechanism responsible for the TLR3 role in neuropathic pain [79]. This indicates that blockade  
9  
10 of TLR3 in spinal cord glial cells may potentially be beneficial in the treatment of neuropathic  
11  
12 pain [83].  
13  
14

15  
16  
17  
18 Using knockout mice it was shown that TLR2 also contributes to nerve injury induced pain  
19  
20 hypersensitivity by activating microglia and astrocytes and inducing proinflammatory gene  
21  
22 expression [79, 81]. It has been proposed that damage to nerve axons may trigger this TLR2  
23  
24 dependent activation of microglia [79].  
25  
26  
27

28  
29  
30  
31 All of these studies suggest that TLRs are important in the molecular pathogenesis of neuropathic  
32  
33 pain and raises the possibility that blockade of TLRs on glia may provide therapeutic benefit in  
34  
35 the treatment of this devastating condition.  
36  
37  
38

## 39 40 41 42 43 **8. Role of TLRs in infectious diseases of the brain**

44  
45  
46  
47 The location of TLR-expressing cells in the brain is indicative that these PRRs are likely to be  
48  
49 important in sensing invading pathogens into this organ. For example microglia expressing TLRs  
50  
51 are located at regions exposed to the circulation such as the circumventricular organs, meninges  
52  
53 and choroid plexus [17, 18]. TLR expression in the CNS is enhanced by bacterial and viral  
54  
55 infection in order to initiate an inflammatory response [17]. Finally stimulation of TLRs on  
56  
57  
58  
59  
60  
61

1  
2  
3  
4 microglia and astrocytes with either TLR ligands or pathogens results in the production of a  
5  
6 variety of inflammatory mediators [17].  
7  
8  
9

## 10 11 **8.1 TLRs and Cerebral malaria** 12 13

14  
15  
16 It has been established that TLRs recognise malaria parasites and their metabolites and studies  
17  
18 have been undertaken to understand the role of TLRs in malaria infection. In particular attempts  
19  
20 have been made to address the role of TLRs in the development of cerebral malaria (CM), which  
21  
22 is a lethal complication of malaria infection in humans [89]. This condition is characterised by  
23  
24 reduced consciousness or coma and generalized convulsions [90]. In one study it has been  
25  
26 demonstrated that the pathogenesis of CM is mediated by MyD88 dependent TLR signalling.  
27  
28  
29 Compared with WT and TRIF knockout (KO) mice, survival but not parasitemia was increased in  
30  
31 the TLR2, TLR9 and MyD88 knockout mice following plasmodium berghei ANKA (PbA)  
32  
33 infection. This suggests that this TLR axis does not confer protective immunity to PAb infection  
34  
35 but rather contributes to the pathogenesis of infection [91]. In contrast TLR 4, 5 and 7 showed no  
36  
37 involvement in response to infection with PbA, as mice lacking these TLRs exhibited no survival  
38  
39 benefit compared with WT mice. While systemic parasitemia was comparable in the WT, TRIF  
40  
41 and MyD88 knockouts, parasite sequestration and hemozoin load in the blood vessels of the brain  
42  
43 were lower in the MyD88 KO mice [91]. Furthermore a number of pathological features in the  
44  
45 brain associated with CM were dependent upon MyD88, such as the infiltration of CD8+, CCR5+  
46  
47 T cells, CD11c+ dendritic cells and the increased expression of inflammatory response genes  
48  
49 Granzyme B, Lipocalin 2, Ccl3 and Ccr5 [91]. Further evidence in support of a role of TLR2 and  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 TLR9 involvement in malaria comes from the observation that Glycosylphosphatidylinositol  
5  
6 (GPI) and hemozoin have been reported to be ligands for TLR2 and TLR9 respectively [91].  
7  
8  
9

10  
11 In contrast a study using mice lacking TLR1, 2, 3, 4, 6, 7, 9, CD14, MyD88, Mal or TRIF,  
12  
13 showed that these mice exhibited similar sensitivity to lethal CM development following PbA  
14  
15 infection compared to WT mice. In addition vascular permeability of the brain did not differ  
16  
17 between WT and MyD88 deficient mice with CM [89]. This led to the authors to conclude that  
18  
19 the development of CM following PbA infection is independent of TLRs and their signalling  
20  
21 adaptors.  
22  
23  
24  
25

26  
27  
28 A further study again using PbA infection as a model of CM examined the role of TLRs. Using  
29  
30 triple TLR2/4/9-deficient mice it was demonstrated that the development of CM was not affected  
31  
32 by the absence of these TLRs [90]. In these mice the induction of ICAM1 on brain endothelium  
33  
34 and recruitment of T cells to the brain were unaffected. This is in agreement with the study of  
35  
36 Togbe et al [89]. The reason for these conflicting observations is unknown and confusing since  
37  
38 these studies all used similar models of CM. Therefore the significance if any, of the detection of  
39  
40 malaria products by TLR2 and TLR9 to the development of CM is currently unknown. However  
41  
42 despite the conflicting data regarding TLRs in murine models of CM, a polymorphisms in TLR9  
43  
44 has been associated with altered levels of IFN $\gamma$  in children with CM [92].  
45  
46  
47  
48  
49  
50  
51  
52

## 53 **8.2 TLRs and Herpes Simplex Encephalitis**

54  
55  
56

57 Studies in mice have shown that microglia respond to herpes simplex virus-1 (HSV-1) infection  
58  
59 by the TLR2 dependent production of a range of cytokines and chemokines. Since mice lacking  
60  
61

1  
2  
3  
4 TLR2 exhibit reduced mortality and neuroinflammation from brain infection by HSV-1, it is  
5  
6 suggested that TLR2 can mediate the pathogenesis of this viral infection [93, 94]. It has also been  
7  
8 found that TLR2 mediates apoptosis in microglia in response to HSV infection [95]. A recent *in*  
9  
10 *vitro* study has shown that microglia respond to HSV-1 infection by producing ROS leading to  
11  
12 neurotoxicity, an effect which was reduced in microglia from mice lacking TLR2 [96]. It appears  
13  
14 therefore that TLR2 confers detrimental immunity to HSV infection.  
15  
16  
17  
18  
19  
20

21 Considering that TLRs detect multiple PAMPs it is likely that multiple TLRs can act together to  
22  
23 provide a comprehensive immune responses to a specific viral infection. In the case of HSV this  
24  
25 appears to be the case. TLR2 detects an unknown molecule from the HSV viron, while TLR9  
26  
27 detects CpG [97]. Consequently it has been found that TLR2 and TLR9 function synergistically  
28  
29 to respond to HSV infection in the brain [97]. HSV loads in the brain were found to be greater in  
30  
31 the TLR2/9 double knockouts compared with brains from either the single knockouts. The  
32  
33 expression of TNF $\alpha$  and CXCL9 in response to HSV were also dependent on TLR2 and TLR9.  
34  
35  
36 So while TLR2 in isolation might contribute to the pathogenesis of HSV, mediated by the release  
37  
38 of cytokines and chemokines, TLR2 and TLR9 together appear to be required for an effective  
39  
40 immune response to HSV, particularly in the brain [97]. Further evidence in support of a role for  
41  
42 TLRs in response to HSV infection came from the observation that MyD88 knockout mice  
43  
44 develop lethal encephalitis following intranasal infection with HSV [97]. Therefore TLR2 and  
45  
46 TLR9 function together to confer resistance against HSV infection in the brain.  
47  
48  
49  
50  
51  
52  
53  
54

55 To date most studies concerning TLRs and HSV have used mice and there is a lack of human  
56  
57 data in this area. However one study has reported that TLR3 is important in the human response  
58  
59  
60  
61

1  
2  
3  
4 to HSV induced encephalitis (HSE). In this study it was found that two children with a  
5  
6 heterozygous mutation in TLR3 were specifically predisposed to HSE [98].  
7  
8  
9

10  
11 The relevance of TLR3 in conferring immunity against HSV in humans is supported by the  
12  
13 finding that alterations in signalling proteins downstream of TLR3 predispose to HSE. It has been  
14  
15 reported recently that a young adult with a childhood history of HSE harboured a mutation in  
16  
17 TRAF3. This mutation, a C to T at nucleotide 352 in exon 4, resulted in the substitution of a  
18  
19 tryptophan for an arginine at position 118 (R118W). This mutation resulted in loss of TRAF3  
20  
21 expression and behaved in an autosomal dominant fashion. This mutation impaired TLR3  
22  
23 induction of IFN. Therefore the immunity mediated by TLR3 against HSV-1 in the CNS is  
24  
25 dependent upon TRAF3 [99]. Interestingly the young adult described is otherwise healthy and  
26  
27 critically has normal resistance to other viruses. It has been proposed that the weak yet detectable  
28  
29 TRAF3 expression in this individual account for survival into adulthood [99]. Other TLRs that  
30  
31 are implicated in conferring protective immunity against HSE in humans, are TLR 7, 8 and 9,  
32  
33 since an autosomal recessive mutation in UNC93B, which is required for the proper signalling of  
34  
35 these TLRs, also predisposed to HSE [100] (Table 3).  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 **8.3 TLRs in response to bacterial meningitis**

46  
47  
48  
49  
50

51 Meningitis or inflammation of the meninges can be caused by a wide variety of bacteria. The  
52  
53 TLR response to bacteria that can cause meningitis has been evaluated in a number of mouse  
54  
55 models of this disease. The gram positive bacteria group B streptococcus (GBS) is a major cause  
56  
57 of meningitis in neonates. *In vitro* studies showed that heat inactivated GBS and a secreted factor  
58  
59  
60  
61

1  
2  
3  
4 from GBS induced neuronal apoptosis via the TLR2 and MyD88 dependent production of NO  
5  
6 from microglia. This observation is indicative of a mode of neurodegeneration that may  
7  
8 contribute to the disease process of GBS meningitis in neonates [17]. Furthermore GBS can  
9  
10 trigger microglial apoptosis in a pathway dependent upon TLR2 and caspase 8 [101]. A  
11  
12 functional interaction between TLR2 and GBS is consistent with other studies which indicate that  
13  
14 TLR2 is required for host defence against GBS in other disease settings such as arthritis and  
15  
16  
17  
18  
19 sepsis [102].  
20  
21  
22

23  
24 In a murine meningitis model using *streptococcus pneumoniae*, it was demonstrated that mice  
25  
26 lacking TLR2 showed an earlier time of death compared with WT mice. When compared with  
27  
28 the WT mice the TLR2 knockout mice had greater bacterial loads in the brain, indicating that  
29  
30 TLR2 conferred protective immunity against *streptococcus pneumoniae* infection in the CNS  
31  
32  
33 [103, 104].  
34  
35  
36  
37

38  
39 *Citrobacter koseri* is an example of a gram negative bacteria which causes meningitis in  
40  
41 neonates. The contribution of TLRs to immunity against this pathogen was also evaluated in  
42  
43 mice. It was shown that microglia from both TLR4 and MyD88 KO mice showed reduced  
44  
45 proinflammatory cytokine responses to *C. koseri* compared with WT microglia, suggesting that  
46  
47 the inflammatory response of microglia to *C. koseri* is dependent upon TLR4 and MyD88 [105]  
48  
49  
50 (Table 2).  
51  
52  
53  
54

55  
56 The presence of polymorphisms in the TLR system affecting meningitis susceptibility in humans  
57  
58 suggest that TLRs might be important in this illness, in particular those caused by *mycobacterium*  
59  
60  
61



1  
2  
3  
4 *tuberculosis*. It was found that a polymorphism in Mal C558T, and a TLR2 polymorphism,  
5  
6 T597C, is associated with susceptibility to meningitis caused by TB  
7  
8  
9 [106, 107] (Table 3). However such data is limited and further work is required in this area to  
10  
11 determine the contribution of TLRs to human meningitis.  
12  
13  
14  
15  
16  
17  
18

## 19 **9. Future perspectives**

20  
21  
22  
23

24 In the past decade huge advances have been made in understanding innate immunity and there is  
25  
26 a growing appreciation that the innate immune system is important in the CNS. In particular there  
27  
28 is accumulating evidence that TLRs contribute to the pathogenesis of diseases of the CNS as  
29  
30 eliciting their signalling pathways can be detrimental and lead to neurotoxicity. Conversely it is  
31  
32 now known that triggering TLR signalling in the appropriate context in the CNS can confer  
33  
34 neuroprotection and is therefore beneficial in some disease circumstances such as stroke.  
35  
36  
37  
38  
39  
40  
41

42 It may be possible to treat neurodegenerative disorders in the future with drugs that stimulates  
43  
44 neurogenesis from endogenous NPCs. For example in ischaemic models it has been shown that  
45  
46 new neurons are not only generated but also functionally integrate and enhance cognitive  
47  
48 function which suggests that the use of drugs that trigger neurogenesis may be beneficial in  
49  
50 stroke [21]. Alternatively the introduction of transplanted NPC from transdifferentiated stem cells  
51  
52 from non-neural tissue such as the skin may be used. The use of NPC transdifferentiated from the  
53  
54 patient's own non-neural stem cells to generate new neurons would avoid problems associated  
55  
56 with host-versus-donor rejection [21]. In addition to this much work will be required to  
57  
58  
59  
60  
61

1  
2  
3  
4 understand how new neurons survive and integrate in order to be properly functional, therefore  
5  
6 the processes following neuronal generation may be manipulated therapeutically in diseases of  
7  
8 the CNS [21]. The finding that TLRs modulate adult neurogenesis [108] suggests that TLR  
9  
10 manipulation may, in the future, be beneficial in therapies aimed at enhancing neurogenesis.  
11  
12  
13  
14  
15  
16

17 It is hoped that a more complete understanding of TLRs and their signalling pathways in the CNS  
18  
19 will lead to the development of more effective treatments for a number of CNS diseases such as  
20  
21 stroke, Alzheimers, MS and infectious diseases. However in order for this to occur better tools to  
22  
23 study human TLRs are needed. There is a requirement for commercially available reliable and  
24  
25 specific antibodies to human TLRs and their signalling proteins [19, 109]. The availability of  
26  
27 such specific antibodies would allow for careful analysis of TLR expression and function. In  
28  
29 addition better and more relevant animal models of human CNS diseases are required, especially  
30  
31 those which take into account co-morbidities and address age related factors of disease  
32  
33 development such as Alzheimer's and stroke [59]. Furthermore an area that remains poorly  
34  
35 understood is the role of negative regulators of TLR signalling in CNS diseases [19].  
36  
37  
38  
39  
40  
41  
42  
43

44 One of many concerns regarding the usefulness of mice models to human brain diseases where  
45  
46 TLRs are implicated, is the fact that the expression pattern of TLRs differs between both species,  
47  
48 with some striking examples. For instance and as stated above, human astrocytes express only  
49  
50 TLR3 [10], while murine astrocytes express TLR2, 4, 5 and 9 mRNA [11]. Therefore the use of  
51  
52 mouse models will have to be complemented by the use of relevant human cell and tissue culture  
53  
54 models of CNS diseases [59].  
55  
56  
57  
58  
59  
60  
61

1  
2  
3  
4 Since TLRs are implicated in the pathogenesis of a wide range of CNS diseases, the development  
5  
6 of therapeutics that target TLRs and their associated signalling pathways may be useful in the  
7  
8 treatment of more than one condition, and increases the attractiveness of these PRRs to  
9  
10 manipulation. However the manipulation of TLRs will have to be carefully considered. For  
11  
12 example the potential use of TLR inhibitors in the treatment of conditions such as neuropathic  
13  
14 pain may have unforeseen consequences on the influence that TLRs have in neuroprotection.  
15  
16 Conversely stimulating TLRs to enhance immunity to infectious diseases may lead to  
17  
18 neuroinflammation and neurotoxicity. Therefore the complexity of homeostatic roles that TLRs  
19  
20 possess presents a huge challenge to their possible therapeutic manipulation. Nevertheless it is  
21  
22 anticipated that further discoveries will lead to a better understanding of the role of TLRs in non  
23  
24 infectious and infectious diseases of the CNS which may lead to better treatments for these  
25  
26 conditions.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

### 37 **Disclosure**

38  
39 The authors have nothing to disclose.  
40  
41  
42  
43

### 44 **Acknowledgements**

45  
46  
47  
48  
49  
50 This work is supported by the Health Research Board (Post-Doctoral Research Fellowship to  
51  
52 MC) and Science Foundation Ireland.  
53  
54  
55  
56  
57  
58  
59  
60  
61

**Abbreviations Used**

AD: Alzheimer's disease

ALRs: Aim2 like receptors

A $\beta$ : Amyloid $\beta$

BBB: Blood brain barrier

CARD: caspase activating and recruitment domain

CB: Cerebral malaria

CFA: Complete freunds adjuvant

CNS: Central nervous system

CpG: Cytosine phosphate guanosine

DAMPs: danger associates molecular patterns

DCs: dendritic cells

dsRNA: Double-stranded RNA

EAE: Experimental Autoimmune Encephalitis

EGF: Epidermal growth factor

ERK: extracellular signal-regulated kinase

FADD: Fas-associated death domain

FA $\beta$ : fibrillar A $\beta$

FPRL1: Formyl peptide receptor-like 1

GBS: Group B streptococcus

GPI: Glycosylphosphatidylinositol

HMGB1: High mobility group box 1 protein

HSE: Herpes simplex virus induced encephalitis

HSP: Heat shock proteins heat shock proteins

1  
2  
3  
4 HSV: Herpes simplex virus

5  
6 IL-1 $\beta$ : Interleukin-1 $\beta$

7  
8  
9 IL-6: Interleukin-6

10  
11 iNOS: inducible nitric oxide synthase

12  
13 IRAK: IL-1 receptor-associated kinases

14  
15  
16 IRF: Interferon Regulatory Factor

17  
18 JNK: c-Jun N-terminal kinase

19  
20  
21 KO: Knockout

22  
23 LPS: Lipopolysaccharide

24  
25 Mal: MyD88 adaptor-like protein

26  
27  
28 MAPK: Mitogen-activated protein kinase

29  
30  
31 MMPs: Matrix metalloproteinases

32  
33 MS: Multiple sclerosis

34  
35  
36 MyD88: Myeloid differentiation factor 88

37  
38 NACHT: domain present in NAIP, CIITA, HET-E, TP-1

39  
40  
41 NAP1: NAK-associated protein 1

42  
43 NF $\kappa$ B: Nuclear factor  $\kappa$ B

44  
45  
46 NLRs: Nod-like Receptors

47  
48 NO: Nitric oxide

49  
50  
51 NPCs: Neural progenitor cells

52  
53 PAMP: Pathogen-associated molecular

54  
55  
56 Pattern

57  
58 polyI:C: polyinosine-deoxycytidylic acid

59  
60  
61 PRRs: Pattern recognition receptors

62  
63  
64  
65 35

1  
2  
3  
4 RIP1: receptor interacting protein 1  
5

6 RLRs: Rig like Receptors RLRs  
7

8 ROS: Reactive oxygen species  
9

10 SARM: Sterile  $\alpha$ -and armadillo-motif containing protein  
11

12 SINTBAD: Similar to NAP1 TBK1 adaptor  
13

14 TAK1: transforming growth factor- $\beta$ -activated protein kinase 1  
15

16 TANK: TRAF family member-associated NF $\kappa$ B activator  
17

18 TBK1: TANK-binding kinase  
19

20 TIR: Toll/IL-1 receptor  
21

22 TLR: Toll-like receptor  
23

24 TNF $\alpha$ : Tumor necrosis factor  $\alpha$   
25

26 TRADD: TNF-R-associated death domain  
27

28 TRAF6: tumor necrosis factor receptor associated factor 6  
29

30 TRAM: TRIF-related adaptor protein  
31

32 TRIF: TIR domain-containing adaptor  
33

34 VEGF: Vascular endothelial growth factor  
35

36 WT: Wild type  
37

## 38 39 40 41 42 43 44 45 46 47 48 49 **References**

50  
51  
52 [1] Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 140:805-20.  
53

54 [2] Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an  
55 innate immune sensor for intracellular DNA. Nat Immunol 11:997-1004.  
56  
57  
58

- 1  
2  
3  
4 [3] O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of  
5 progress. *Immunol Rev* 2008;226:10-8.  
6  
7  
8  
9 [4] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on  
10 Toll-like receptors. *Nat Immunol* 11:373-84.  
11  
12  
13 [5] O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like  
14 receptor signalling. *Nat Rev Immunol* 2007;7:353-64.  
15  
16  
17  
18 [6] Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG. The human  
19 adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor  
20 signaling. *Nat Immunol* 2006;7:1074-81.  
21  
22  
23  
24 [7] Keating SE, Maloney GM, Moran EM, Bowie AG. IRAK-2 participates in multiple toll-  
25 like receptor signaling pathways to NFkappaB via activation of TRAF6 ubiquitination. *J*  
26 *Biol Chem* 2007;282:33435-43.  
27  
28  
29  
30 [8] Banerjee A, Gugasyan R, McMahon M, Gerondakis S. Diverse Toll-like receptors utilize  
31 Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. *Proc*  
32 *Natl Acad Sci U S A* 2006;103:3274-9.  
33  
34  
35 [9] Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor  
36 signaling. *Cell Mol Life Sci*.  
37  
38  
39 [10] Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinel E. Preferential expression  
40 and function of Toll-like receptor 3 in human astrocytes. *J Neuroimmunol* 2005;159:12-9.  
41  
42  
43 [11] Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like  
44 receptors for bacterial products. *Glia* 2003;43:281-91.  
45  
46  
47 [12] Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. Pivotal role for  
48 neuronal Toll-like receptors in ischemic brain injury and functional deficits. *Proc Natl*  
49 *Acad Sci U S A* 2007;104:13798-803.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61

- 1  
2  
3  
4 [13] Mishra BB, Mishra PK, Teale JM. Expression and distribution of Toll-like receptors in  
5  
6 the brain during murine neurocysticercosis. *J Neuroimmunol* 2006;181:46-56.  
7  
8  
9 [14] Lafon M, Megret F, Lafage M, Prehaud C. The innate immune facet of brain: human  
10  
11 neurons express TLR-3 and sense viral dsRNA. *J Mol Neurosci* 2006;29:185-94.  
12  
13  
14 [15] Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive  
15  
16 immune responses through multiple TLRs. *J Immunol* 2004;173:3916-24.  
17  
18  
19 [16] Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, et al. TLR signaling  
20  
21 tailors innate immune responses in human microglia and astrocytes. *J Immunol*  
22  
23 2005;175:4320-30.  
24  
25  
26 [17] Carpentier PA, Duncan DS, Miller SD. Glial toll-like receptor signaling in central  
27  
28 nervous system infection and autoimmunity. *Brain Behav Immun* 2008;22:140-7.  
29  
30  
31 [18] Hanisch UK, Johnson TV, Kipnis J. Toll-like receptors: roles in neuroprotection? *Trends*  
32  
33 *Neurosci* 2008;31:176-82.  
34  
35  
36 [19] Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in  
37  
38 Toll-like receptor-mediated neuronal injury. *Glia* 58:253-63.  
39  
40  
41 [20] Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and  
42  
43 Alzheimer's disease. *Neurobiol Aging* 2000;21:383-421.  
44  
45  
46 [21] Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying  
47  
48 effects in neurogenesis: relevance to the pathogenesis of brain injury and  
49  
50 neurodegenerative disorders. *J Neurochem* 2009;108:1343-59.  
51  
52  
53 [22] Lehnardt S, Schott E, Trimbuch T, Laubisch D, Krueger C, Wulczyn G, et al. A vicious  
54  
55 cycle involving release of heat shock protein 60 from injured cells and activation of toll-  
56  
57 like receptor 4 mediates neurodegeneration in the CNS. *J Neurosci* 2008;28:2320-31.  
58  
59  
60  
61  
62  
63  
64  
65



- 1  
2  
3  
4 [23] Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous  
5 system immunity and glioma immunology. *J Clin Neurosci* 17:6-10.  
6  
7  
8  
9 [24] Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic  
10 models. *Annu Rev Neurosci* 1998;21:479-505.  
11  
12  
13  
14 [25] Sudoh S, Kawamura Y, Sato S, Wang R, Saido TC, Oyama F, et al. Presenilin 1  
15 mutations linked to familial Alzheimer's disease increase the intracellular levels of  
16 amyloid beta-protein 1-42 and its N-terminally truncated variant(s) which are generated at  
17 distinct sites. *J Neurochem* 1998;71:1535-43.  
18  
19  
20  
21  
22  
23 [26] Iribarren P, Zhou Y, Hu J, Le Y, Wang JM. Role of formyl peptide receptor-like 1  
24 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. *Immunol Res*  
25 2005;31:165-76.  
26  
27  
28  
29  
30  
31 [27] Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE. Gene expression changes  
32 by amyloid beta peptide-stimulated human postmortem brain microglia identify activation  
33 of multiple inflammatory processes. *J Leukoc Biol* 2006;79:596-610.  
34  
35  
36  
37  
38 [28] Murphy GM, Jr., Yang L, Cordell B. Macrophage colony-stimulating factor augments  
39 beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by  
40 microglial cells. *J Biol Chem* 1998;273:20967-71.  
41  
42  
43  
44  
45 [29] Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate A  
46 beta(1--42)-induced cytokine and chemokine production in primary murine microglia and  
47 a human monocyte cell line. *J Neuroimmunol* 2001;113:49-62.  
48  
49  
50  
51  
52  
53 [30] Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM, Jr., et al.  
54 Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in  
55 vitro. *Glia* 2001;35:72-9.  
56  
57  
58  
59  
60  
61

- 1  
2  
3  
4 [31] Yates SL, Burgess LH, Kocsis-Angle J, Antal JM, Dority MD, Embury PB, et al.  
5  
6 Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and  
7  
8 chemokine production by THP-1 cells and murine microglia. *J Neurochem* 2000;74:1017-  
9  
10 25.  
11  
12  
13  
14 [32] Jana M, Palencia CA, Pahan K. Fibrillar amyloid-beta peptides activate microglia via  
15  
16 TLR2: implications for Alzheimer's disease. *J Immunol* 2008;181:7254-62.  
17  
18  
19 [33] Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, et al. The LPS receptor  
20  
21 (CD14) links innate immunity with Alzheimer's disease. *FASEB J* 2004;18:203-5.  
22  
23  
24 [34] Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, et al. LPS  
25  
26 receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. *Brain*  
27  
28 2005;128:1778-89.  
29  
30  
31 [35] Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, et al. Role of the toll-like  
32  
33 receptor 4 in neuroinflammation in Alzheimer's disease. *Cell Physiol Biochem*  
34  
35 2007;20:947-56.  
36  
37  
38 [36] Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, et al. Screening of innate  
39  
40 immune receptors in neurodegenerative diseases: a similar pattern. *Neurobiol Aging*  
41  
42 2009;30:759-68.  
43  
44  
45 [37] Minoretto P, Gazzaruso C, Vito CD, Emanuele E, Bianchi M, Coen E, et al. Effect of the  
46  
47 functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset  
48  
49 Alzheimer's disease. *Neurosci Lett* 2006;391:147-9.  
50  
51  
52  
53 [38] Frank S, Copanaki E, Burbach GJ, Muller UC, Deller T. Differential regulation of toll-  
54  
55 like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic  
56  
57 mice. *Neurosci Lett* 2009;453:41-4.  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 [39] Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 and toll-like receptors 2  
5 and 4 are required for fibrillar A{beta}-stimulated microglial activation. *J Neurosci*  
6 2009;29:11982-92.  
7  
8  
9  
10  
11 [40] Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface  
12 receptor complex for fibrillar beta-amyloid mediates microglial activation. *J Neurosci*  
13 2003;23:2665-74.  
14  
15  
16  
17  
18 [41] Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. *Neurobiol*  
19 *Dis* 37:503-9.  
20  
21  
22  
23 [42] Cui YH, Le Y, Gong W, Proost P, Van Damme J, Murphy WJ, et al. Bacterial  
24 lipopolysaccharide selectively up-regulates the function of the chemotactic peptide  
25 receptor formyl peptide receptor 2 in murine microglial cells. *J Immunol* 2002;168:434-  
26 42.  
27  
28  
29  
30  
31  
32  
33 [43] Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, et al. Activation of Toll-like  
34 receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid  
35 beta peptide. *J Biol Chem* 2006;281:3651-9.  
36  
37  
38  
39  
40 [44] Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, et al. Toll-like receptor-  
41 4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid  
42 peroxidation product 4-hydroxynonenal. *Exp Neurol* 2008;213:114-21.  
43  
44  
45  
46  
47 [45] Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-  
48 amyloid and IgGs are differentially regulated by proinflammatory cytokines. *J Neurosci*  
49 2005;25:8240-9.  
50  
51  
52  
53  
54  
55 [46] Trudler D, Farfara D, Frenkel D. Toll-like receptors expression and signaling in glia cells  
56 in neuro-amyloidogenic diseases: towards future therapeutic application. *Mediators*  
57 *Inflamm* 2010.  
58  
59  
60  
61

- 1  
2  
3  
4 [47] Doi Y, Mizuno T, Maki Y, Jin S, Mizoguchi H, Ikeyama M, et al. Microglia activated  
5  
6 with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid {beta}  
7  
8 neurotoxicity in in vitro and in vivo models of Alzheimer's disease. *Am J Pathol*  
9  
10 2009;175:2121-32.  
11  
12  
13 [48] Fischer M, Ehlers M. Toll-like receptors in autoimmunity. *Ann N Y Acad Sci*  
14  
15 2008;1143:21-34.  
16  
17  
18 [49] Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, et al. Innate immunity  
19  
20 mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. *J*  
21  
22 *Clin Invest* 2006;116:456-64.  
23  
24  
25 [50] Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis.  
26  
27 *Annu Rev Immunol* 1990;8:579-621.  
28  
29  
30 [51] O'Connor RA, Prendergast CT, Sabatos CA, Lau CW, Leech MD, Wraith DC, et al.  
31  
32 Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system  
33  
34 during experimental autoimmune encephalomyelitis. *J Immunol* 2008;181:3750-4.  
35  
36  
37 [52] Steinman L. A rush to judgment on Th17. *J Exp Med* 2008;205:1517-22.  
38  
39  
40 [53] Waldner H. The role of innate immune responses in autoimmune disease development.  
41  
42 *Autoimmun Rev* 2009;8:400-4.  
43  
44  
45 [54] Marta M, Andersson A, Isaksson M, Kampe O, Lobell A. Unexpected regulatory roles of  
46  
47 TLR4 and TLR9 in experimental autoimmune encephalomyelitis. *Eur J Immunol*  
48  
49 2008;38:565-75.  
50  
51  
52 [55] Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B. Cutting Edge: TLR3 stimulation  
53  
54 suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-  
55  
56 beta. *J Immunol* 2006;177:7505-9.  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 [56] Fernandez M, Montalban X, Comabella M. Orchestrating innate immune responses in  
5 multiple sclerosis: molecular players. *J Neuroimmunol* 225:5-12.  
6  
7  
8  
9 [57] Lampropoulou V, Hoehlig K, Roch T, Neves P, Calderon Gomez E, Sweenie CH, et al.  
10 TLR-activated B cells suppress T cell-mediated autoimmunity. *J Immunol*  
11 2008;180:4763-73.  
12  
13  
14  
15 [58] Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in  
16 the human central nervous system. *J Neuropathol Exp Neurol* 2002;61:1013-21.  
17  
18  
19 [59] Downes CE, Crack PJ. Neural injury following stroke: are Toll-like receptors the link  
20 between the immune system and the CNS? *Br J Pharmacol* 160:1872-88.  
21  
22  
23  
24 [60] Hartl R, Schurer L, Schmid-Schonbein GW, del Zoppo GJ. Experimental antileukocyte  
25 interventions in cerebral ischemia. *J Cereb Blood Flow Metab* 1996;16:1108-19.  
26  
27  
28  
29 [61] Qiu J, Xu J, Zheng Y, Wei Y, Zhu X, Lo EH, et al. High-mobility group box 1 promotes  
30 metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia.  
31 *Stroke* 41:2077-82.  
32  
33  
34  
35 [62] Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S, et al. Toll-  
36 like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective  
37 effects against focal cerebral ischemia. *Neuroscience* 171:258-67.  
38  
39  
40  
41 [63] Hua F, Wang J, Sayeed I, Ishrat T, Atif F, Stein DG. The TRIF-dependent signaling  
42 pathway is not required for acute cerebral ischemia/reperfusion injury in mice. *Biochem*  
43 *Biophys Res Commun* 2009;390:678-83.  
44  
45  
46  
47 [64] Ziegler G, Harhausen D, Schepers C, Hoffmann O, Rohr C, Prinz V, et al. TLR2 has a  
48 detrimental role in mouse transient focal cerebral ischemia. *Biochem Biophys Res*  
49 *Commun* 2007;359:574-9.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61

- 1  
2  
3  
4 [65] Abe T, Shimamura M, Jackman K, Kurinami H, Anrather J, Zhou P, et al. Key role of  
5  
6 CD36 in Toll-like receptor 2 signaling in cerebral ischemia. *Stroke* 41:898-904.  
7  
8  
9 [66] Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, et al. Systemic  
10  
11 lipopolysaccharide protects the brain from ischemic injury by reprogramming the  
12  
13 response of the brain to stroke: a critical role for IRF3. *J Neurosci* 2009;29:9839-49.  
14  
15  
16 [67] Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, et al. Toll-like  
17  
18 receptor 9: a new target of ischemic preconditioning in the brain. *J Cereb Blood Flow*  
19  
20 *Metab* 2008;28:1040-7.  
21  
22  
23 [68] Pradillo JM, Fernandez-Lopez D, Garcia-Yebenes I, Sobrado M, Hurtado O, Moro MA,  
24  
25 et al. Toll-like receptor 4 is involved in neuroprotection afforded by ischemic  
26  
27 preconditioning. *J Neurochem* 2009;109:287-94.  
28  
29  
30 [69] Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults.  
31  
32  
33 *Lancet* 2003;361:323-31.  
34  
35  
36 [70] Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB. Innate immune functions of  
37  
38 microglia isolated from human glioma patients. *J Transl Med* 2006;4:15.  
39  
40  
41 [71] Grauer OM, Molling JW, Bennink E, Toonen LW, Suttmuller RP, Nierkens S, et al. TLR  
42  
43 ligands in the local treatment of established intracerebral murine gliomas. *J Immunol*  
44  
45 2008;181:6720-9.  
46  
47  
48 [72] Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre JY, et al. Expression of TLR9  
49  
50 within human glioblastoma. *J Neurooncol* 2008;88:19-25.  
51  
52  
53 [73] Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B. Induction of anti-  
54  
55 glioma natural killer cell response following multiple low-dose intracerebral CpG  
56  
57 therapy. *Clin Cancer Res* 16:3399-408.  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 [74] Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, et al.  
5  
6 CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth  
7  
8 and efficiently suppress antiglioma immune responses in vivo. *Int J Cancer* 2007;121:95-  
9  
10 105.  
11  
12  
13  
14 [75] Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, et al. Phase 1 trial  
15  
16 of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. *Neuro Oncol*  
17  
18 2006;8:60-6.  
19  
20  
21 [76] Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M, et al. Intracerebral  
22  
23 administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II  
24  
25 study. *Neuro Oncol* 12:401-8.  
26  
27  
28 [77] Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune  
29  
30 cells: a double-edged sword. *Oncogene* 2008;27:218-24.  
31  
32  
33 [78] Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological  
34  
35 pain. *Trends Neurosci* 2001;24:450-5.  
36  
37  
38 [79] Kim D, Kim MA, Cho IH, Kim MS, Lee S, Jo EK, et al. A critical role of toll-like  
39  
40 receptor 2 in nerve injury-induced spinal cord glial cell activation and pain  
41  
42 hypersensitivity. *J Biol Chem* 2007;282:14975-83.  
43  
44  
45 [80] Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate  
46  
47 exaggerated pain states: implications for clinical pain. *Adv Exp Med Biol* 2003;521:1-21.  
48  
49  
50 [81] Shi XQ, Zekki H, Zhang J. The role of TLR2 in nerve injury-induced neuropathic pain is  
51  
52 essentially mediated through macrophages in peripheral inflammatory response. *Glia*  
53  
54 59:231-41.  
55  
56  
57 [82] Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. *Nat*  
58  
59 *Rev Neurosci* 2009;10:23-36.  
60  
61

- 1  
2  
3  
4 [83] Obata K, Katsura H, Miyoshi K, Kondo T, Yamanaka H, Kobayashi K, et al. Toll-like  
5  
6 receptor 3 contributes to spinal glial activation and tactile allodynia after nerve injury. *J*  
7  
8 *Neurochem* 2008;105:2249-59.  
9  
10  
11 [84] DeLeo JA, Yeziarski RP. The role of neuroinflammation and neuroimmune activation in  
12  
13 persistent pain. *Pain* 2001;90:1-6.  
14  
15  
16 [85] Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain  
17  
18 enhancement. *Neurosignals* 2005;14:166-74.  
19  
20  
21 [86] Cao L, Tanga FY, Deleo JA. The contributing role of CD14 in toll-like receptor 4  
22  
23 dependent neuropathic pain. *Neuroscience* 2009;158:896-903.  
24  
25  
26 [87] Tanga FY, Nutile-McMenemy N, DeLeo JA. The CNS role of Toll-like receptor 4 in  
27  
28 innate neuroimmunity and painful neuropathy. *Proc Natl Acad Sci U S A* 2005;102:5856-  
29  
30 61.  
31  
32  
33 [88] Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioid-induced glial  
34  
35 activation: improving the clinical efficacy of opioids by targeting glia. *Trends Pharmacol*  
36  
37 *Sci* 2009;30:581-91.  
38  
39  
40 [89] Togbe D, Schofield L, Grau GE, Schnyder B, Boissay V, Charron S, et al. Murine  
41  
42 cerebral malaria development is independent of toll-like receptor signaling. *Am J Pathol*  
43  
44 2007;170:1640-8.  
45  
46  
47 [90] Lepenies B, Cramer JP, Burchard GD, Wagner H, Kirschning CJ, Jacobs T. Induction of  
48  
49 experimental cerebral malaria is independent of TLR2/4/9. *Med Microbiol Immunol*  
50  
51 2008;197:39-44.  
52  
53  
54 [91] Coban C, Ishii KJ, Uematsu S, Arisue N, Sato S, Yamamoto M, et al. Pathological role of  
55  
56 Toll-like receptor signaling in cerebral malaria. *Int Immunol* 2007;19:67-79.  
57  
58  
59  
60  
61



- 1  
2  
3  
4 [92] Sam-Agudu NA, Greene JA, Opoka RO, Kazura JW, Boivin MJ, Zimmerman PA, et al.  
5  
6 TLR9 polymorphisms are associated with altered IFN-gamma levels in children with  
7  
8 cerebral malaria. *Am J Trop Med Hyg* 82:548-55.  
9  
10  
11 [93] Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR. Cutting edge: TLR2-  
12  
13 mediated proinflammatory cytokine and chemokine production by microglial cells in  
14  
15 response to herpes simplex virus. *J Immunol* 2005;175:4189-93.  
16  
17  
18 [94] Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, et al. Herpes simplex  
19  
20 virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. *Proc Natl*  
21  
22 *Acad Sci U S A* 2004;101:1315-20.  
23  
24  
25 [95] Aravalli RN, Hu S, Lokensgard JR. Toll-like receptor 2 signaling is a mediator of  
26  
27 apoptosis in herpes simplex virus-infected microglia. *J Neuroinflammation* 2007;4:11.  
28  
29  
30 [96] Schachtele SJ, Hu S, Little MR, Lokensgard JR. Herpes simplex virus induces neural  
31  
32 oxidative damage via microglial cell Toll-like receptor-2. *J Neuroinflammation* 7:35.  
33  
34  
35 [97] Sorensen LN, Reinert LS, Malmgaard L, Bartholdy C, Thomsen AR, Paludan SR. TLR2  
36  
37 and TLR9 synergistically control herpes simplex virus infection in the brain. *J Immunol*  
38  
39 2008;181:8604-12.  
40  
41  
42 [98] Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency  
43  
44 in patients with herpes simplex encephalitis. *Science* 2007;317:1522-7.  
45  
46  
47 [99] Perez de Diego R, Sancho-Shimizu V, Lorenzo L, Puel A, Plancoulaine S, Picard C, et al.  
48  
49 Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3  
50  
51 response and susceptibility to herpes simplex encephalitis. *Immunity* 33:400-11.  
52  
53  
54 [100] Casrouge A, Zhang SY, Eidenschenk C, Jouanguy E, Puel A, Yang K, et al. Herpes  
55  
56 simplex virus encephalitis in human UNC-93B deficiency. *Science* 2006;314:308-12.  
57  
58  
59  
60  
61

- 1  
2  
3  
4 [101] Lehnardt S, Wennekamp J, Freyer D, Liedtke C, Krueger C, Nitsch R, et al. TLR2 and  
5  
6 caspase-8 are essential for group B Streptococcus-induced apoptosis in microglia. *J*  
7  
8 *Immunol* 2007;179:6134-43.  
9
- 10  
11 [102] Puliti M, Uematsu S, Akira S, Bistoni F, Tissi L. Toll-like receptor 2 deficiency is  
12  
13 associated with enhanced severity of group B streptococcal disease. *Infect Immun*  
14  
15 2009;77:1524-31.  
16  
17
- 18  
19 [103] Echchannaoui H, Frei K, Schnell C, Leib SL, Zimmerli W, Landmann R. Toll-like  
20  
21 receptor 2-deficient mice are highly susceptible to *Streptococcus pneumoniae* meningitis  
22  
23 because of reduced bacterial clearing and enhanced inflammation. *J Infect Dis*  
24  
25 2002;186:798-806.  
26  
27
- 28  
29 [104] Koedel U, Angele B, Rupprecht T, Wagner H, Roggenkamp A, Pfister HW, et al. Toll-  
30  
31 like receptor 2 participates in mediation of immune response in experimental  
32  
33 pneumococcal meningitis. *J Immunol* 2003;170:438-44.  
34  
35
- 36  
37 [105] Liu S, Kielian T. Microglial activation by *Citrobacter koseri* is mediated by TLR4- and  
38  
39 MyD88-dependent pathways. *J Immunol* 2009;183:5537-47.  
40
- 41  
42 [106] Hawn TR, Dunstan SJ, Thwaites GE, Simmons CP, Thuong NT, Lan NT, et al. A  
43  
44 polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is  
45  
46 associated with susceptibility to meningeal tuberculosis. *J Infect Dis* 2006;194:1127-34.  
47
- 48  
49 [107] Thuong NT, Hawn TR, Thwaites GE, Chau TT, Lan NT, Quy HT, et al. A polymorphism  
50  
51 in human TLR2 is associated with increased susceptibility to tuberculous meningitis.  
52  
53 *Genes Immun* 2007;8:422-8.  
54
- 55  
56 [108] Rolls A, Shechter R, London A, Ziv Y, Ronen A, Levy R, et al. Toll-like receptors  
57  
58 modulate adult hippocampal neurogenesis. *Nat Cell Biol* 2007;9:1081-8.  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 [109] Saper CB. A guide to the perplexed on the specificity of antibodies. *J Histochem*  
5  
6 *Cytochem* 2009;57:1-5.  
7  
8  
9 [110] Bsibsi M, Persoon-Deen C, Verwer RW, Meeuwssen S, Ravid R, Van Noort JM. Toll-like  
10  
11 receptor 3 on adult human astrocytes triggers production of neuroprotective mediators.  
12  
13 *Glia* 2006;53:688-95.  
14  
15  
16 [111] Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD. Differential  
17  
18 activation of astrocytes by innate and adaptive immune stimuli. *Glia* 2005;49:360-74.  
19  
20  
21 [112] Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches TLR-3-positive  
22  
23 human neurons to become strong producers of beta interferon. *J Virol* 2005;79:12893-  
24  
25 904.  
26  
27  
28 [113] Marta M, Meier UC, Lobell A. Regulation of autoimmune encephalomyelitis by toll-like  
29  
30 receptors. *Autoimmun Rev* 2009;8:506-9.  
31  
32  
33 [114] Lin YC, Chang YM, Yu JM, Yen JH, Chang JG, Hu CJ. Toll-like receptor 4 gene C119A  
34  
35 but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic  
36  
37 Chinese in Taiwan. *Atherosclerosis* 2005;180:305-9.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65**Figure 1. Families of Pattern recognition receptors (PRRs)**

Innate immunity is composed of a number of PRRs and these include Toll-like receptors (TLRs), Nod like receptors (NLRs), Aim2 like receptors (ALRs) and Rig like receptors (RLRs). TLRs expressed on the cell surface sense bacterial products while endosomal TLRs sense bacterial and viral nucleic acids resulting in the expression of proinflammatory cytokines and type 1 IFN. Bacterial products are also sensed by the cytoplasmic NLRs, Nod1 and Nod2 leading to proinflammatory cytokine expression. NALP3, another member of the Nod family and a component of the inflammasome, detects bacteria in addition to environmental toxins and ATP to activate caspase 1. This results in the cleavage of pro-IL-1 to IL-1, leading to its release. Aim2 also activates caspase 1 following the sensing of cytoplasmic DNA, to permit IL-1 release. IFI16, another member of the ALRs, also senses cytoplasmic DNA, however unlike AIM2, IFI16 activates IFN  $\beta$  expression. RLRs such as MDA5 and RIGI sense cytoplasmic viral RNA to activate type 1 IFN expression via the adapter MAVS.

## Figure 2. Signalling from cell surface TLRs

Cell surface TLRs such as TLR4 and TLR5 and heterodimers of TLR1/2 and TLR2/6 detect bacterial products to trigger the TLR intracellular signalling pathways. Activation of TLRs results in the recruitment of the respective adaptors to the cytoplasmic region of the receptors. Recruitment of MyD88 results in the activation of IRAK4 and the phosphorylation of IRAK1. IRAK1 can then bind TRAF6 (not shown). IRAK2 promotes the ubiquitination of TRAF6 that results in the recruitment of the TAB2/3 complex and the activation of TAK1. This leads to the activation of the IKK complex and the movement of NF $\kappa$ B into the nucleus. The IKK complex is also involved in the activation of TPL2 and the stimulation of the ERK MAP kinase pathway via MKK1/2. The ERK pathway contributes to c-FOS and JUN activation, subunits of AP1. In addition TAK1 triggers the activation of the p38 and JNK pathways via MKK3/6 and MKK4 respectively to activate AP1. Activation of NF $\kappa$ B and the MAP kinase pathways results in the expression of proinflammatory cytokines. TLR4 activation by LPS also results in the internalisation of TLR4 to endosomes. Here TLR4 engages with the adaptors TRAM and TRIF to trigger TRAF3 dependent activation of the IKK $\epsilon$ /TBK1 complex, which also contains DDX3. Activation of this complex results in the phosphorylation and dimerisation of IRF3 and IRF7, resulting in their movement into the nucleus and the expression of type 1 interferon.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65**Figure 3. Signalling from endosomal TLRs**

Microbial nucleic acid engagement with the endosomal TLRs triggers the NF $\kappa$ B and MAP kinase pathways similar to the cell surface expressed TLRs as detailed in figure 2. In addition to those pathways TLR7/8 and TLR9 activate the IRAK1/TRAF6 complex via MyD88 and IRAK4. This leads to the activation of IKK $\alpha$  resulting in the phosphorylation and dimerisation of IRF7. These IRF7 dimers translocate into the nucleus to trigger type 1 IFN production.

1  
2  
3  
4  
5 **Table 1:** Comparison of TLR mRNA and protein expression in human and mouse cells  
6  
7 of the CNS  
8  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Accepted Manuscript

1  
2  
3  
4  
5  
6  
7  
8 **Table 2:** Evidence from knockout mice that TLRs are involved in CNS diseases  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 3:** Evidence from human studies implicating TLRs in diseases of the CNS

Accepted Manuscript

<b>Species</b>	<b>Human</b>	<b>mouse</b>	<b>Human</b>	<b>mouse</b>
<b>Molecule Detected</b>	<b>mRNA</b>	<b>mRNA</b>	<b>Protein Immunoreactivity</b>	<b>Protein Immunoreactivity</b>
<b>TLR1</b>	Microglia [16] Astrocytes [16, 110]	Astrocytes [111] Microglia [15]		
<b>TLR2</b>	Microglia [16] Astrocytes [110]	Microglia [15] Astrocytes [11, 111] Neurons [12]		Neurons [12, 13]
<b>TLR3</b>	Microglia [16] Astrocytes [10, 110] Neurons [112]	Astrocytes [111] Microglia [15] Neurons [12]	Astrocytes [58] Neurons [112]	Neurons [12]
<b>TLR4</b>	Microglia [16] Astrocytes [16, 110]	Microglia [15] Astrocytes [11, 111] Neurons [12]	Astrocytes [58]	Neurons [12, 13]
<b>TLR5</b>	Microglia [16] Astrocytes [16]	Microglia [15] Astrocytes [11, 111]		
<b>TLR6</b>	Microglia [16]	Astrocytes [111] Microglia [15]		Neurons [13]
<b>TLR7</b>	Microglia [16]	Astrocytes [111] Microglia [15]		Neurons [13]
<b>TLR8</b>	Microglia [16]	Astrocytes [111] Microglia [15]		Neurons [13]
<b>TLR9</b>	Microglia [16] Astrocytes [16]	Microglia [15] Astrocytes [11, 111]		

<b>Disease</b>	<b>TLR Implicated</b>	<b>Beneficial or Detrimental</b>
<b>Non infectious diseases:</b> Alzheimers Disease	TLR2, TLR4, CD14 [39]	Both beneficial and detrimental
Experimental Autoimmune Encephalitis	MyD88 [54] TLR4 [113] TLR9 [49, 113] TLR2 (expressed on B cells) [57] TLR4 (expressed on B cells) [57]	Detrimental Beneficial Controversial Beneficial Beneficial
Stroke	TLR4 [62] TLR2 [64]	Detrimental Detrimental
Glioma	TLR9 [71]	Beneficial
<b>Infectious Diseases:</b> Cerebral Malaria	Multiple TLRs [89-91]	Controversial
Herpes Simplex Encephalitis	TLR2 [93, 94] TLR2&TLR9 [97]	Detrimental Beneficial
Bacterial meningitis	TLR2 [103, 104] TLR4 [105]	Beneficial Beneficial

<b>Disease</b>	<b>TLR Implicated</b>	<b>Detrimental or Beneficial</b>
<b>No Infectious diseases:</b> Alzheimers	TLR4 polymorphism Asp299Gly [37]  CD14 increased in senile plaques [34]	Beneficial  Unknown
Multiple Sclerosis	Increased TLR3 and TLR4 [58]	Unknown
Stroke	TLR4 polymorphism C119A [114]	Detrimental
Glioma	TLR9 expression evaluated [72]  Phase I clinical trial [75] Phase II clinical trial [76]	Beneficial
<b>Infectious diseases:</b> Cerebral Malaria	TLR9 polymorphisms [92]	Unknown
Herpes Simplex Encephalitis	TLR3 polymorphism P554S [98]  TRAF3 polymorphism R118W [99]  UNC-93B polymorphism (TLR3, 7, 8, 9) [100]	Detrimental  Detrimental  Detrimental
Bacterial meningitis	MAL polymorphism C558T [106] TLR2 polymorphism T597C [107]	Detrimental  Detrimental







